...
首页> 外文期刊>Journal of Alzheimer's disease: JAD >Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo compared to Histology
【24h】

Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo compared to Histology

机译:阿尔茨海默病的超高场MRI:与组织学相比,体内和exvivo中人类脑脑的有效横向松弛率和定量敏感性敏感性

获取原文
获取原文并翻译 | 示例
           

摘要

Alzheimer's disease (AD) is the most common cause of dementia worldwide. So far, diagnosis of AD is only unequivocally defined through postmortem histology. Amyloid plaques are a classical hallmark of AD and amyloid load is currently quantified by Positron Emission tomography (PET) in vivo. Ultra-high field magnetic resonance imaging (UHFMRI) can potentially provide a non-invasive biomarker for AD by allowing imaging of pathological processes at a very-high spatial resolution. The first aim of this work was to reproduce the characteristic cortical pattern previously observed in vivo in AD patients using weighted-imaging at 7T. We extended these findings using quantitative susceptibility mapping (QSM) and quantification of the effective transverse relaxation rate (R-2*) at 9.4T. The second aim was to investigate the origin of the contrast patterns observed in vivo in the cortex of AD patients at 9.4T by comparing quantitative UHF-MRI (9.4T and 14.1T) of postmortem samples with histology. We observed a distinctive cortical pattern in vivo in patients compared to healthy controls (HC), and these findings were confirmed ex vivo. Specifically, we found a close link between the signal changes detected by QSM in the AD sample at 14.1T and the distribution pattern of amyloid plaques in the histological sections of the same specimen. Our findings showed that QSM and R-2* maps can distinguish AD from HC at UHF by detecting cortical alterations directly related to amyloid plaques in AD patients. Furthermore, we provided a method to quantify amyloid plaque load in AD patients at UHF non-invasively.
机译:阿尔茨海默病(AD)是全球痴呆症最常见的原因。到目前为止,AD的诊断只能通过后期组织学不确定地定义。淀粉样蛋白斑块是广告的经典标志,目前通过体内正电子发射断层扫描(PET)量化淀粉样载荷。通过在非常高的空间分辨率下允许病理过程的成像,超高场磁共振成像(UHFMRI)可以为AD提供非侵入性生物标志物。这项工作的首次目的是在AD患者中再现先前在AD患者体内观察到的特征皮质模式,在7T中使用加重成像。我们使用定量敏感性映射(QSM)扩展了这些发现,并在9.4T时定量有效横向松弛率(R-2 *)。第二个目的是通过比较与组织学的定量UHF-MRI(9.4T和14.1T)对39.4T在AD患者皮层中观察到的对比模式的起源。与健康对照(HC)相比,我们观察了患者体内的独特皮质模式,并确认了这些发现。具体地,我们发现在AD样品中的QSM检测到的14.1T中检测到的信号变化与同一样本的组织学部分中的淀粉样蛋白斑块的分布模式之间的密切联系。我们的研究结果表明,QSM和R-2 *地图可以通过检测AD患者中的淀粉样蛋白斑块直接相关的皮质改变来区分UHF的AD。此外,我们提供了一种在非侵入性的UHF下量化AD患者淀粉样蛋白斑块的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号